T-cells Archives

Best in Biotech 13 Mar 2025

Nine biotechs thriving in Seattle in 2025

In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large.

March 13, 2025 - 12 minutesmins - By Roohi Mariam Peter

In Depth 18 Feb 2025

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

T cell engagers represent a novel approach to tuning the immune system to target and kill tumor cells, expanding treatment options for cancer.

February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter

In Depth 12 Feb 2025

Dendritic cell therapy: Diakonos, Northwest Biotherapeutics and Mendus push ahead with next-generation candidates

Find out about the field of dendritic cell therapy, as several companies attempt to bring next-generation candidates through the clinic.

February 12, 2025 - 10 minutesmins - By Willow Shah-Neville

Best in Biotech 31 Oct 2024

Five T cell engager companies you should know about

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

October 31, 2024 - 7 minutesmins - By Willow Shah-Neville

More News! 4 Dec 2023

FDA CAR-T cell therapy warning: Are T cells malignant?

Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […]

December 4, 2023 - 4 minutesmins - By Jules Adam

Podcast 8 Sep 2023

Beyond Biotech podcast 62 – cytokine-based drugs

As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like interleukin 2 (IL-2) […]

September 8, 2023

News and Trends 25 Jul 2023

Crescendo Biologics raises $32M and expands cancer trial

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]

July 25, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […]

July 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 21 Jun 2023

FDA clears T-Cell receptor natural killer cell therapy for sarcoma

Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […]

June 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 15 Jun 2023

IOME Bio claims breakthrough in cancer research

IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in Nature. The company said its work reveals unique insights into the critical importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens the significance […]

June 15, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]

June 1, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T-cells

Nine biotechs thriving in Seattle in 2025

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

Dendritic cell therapy: Diakonos, Northwest Biotherapeutics and Mendus push ahead with next-generation candidates

Five T cell engager companies you should know about

FDA CAR-T cell therapy warning: Are T cells malignant?

Beyond Biotech podcast 62 – cytokine-based drugs

Crescendo Biologics raises $32M and expands cancer trial

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

FDA clears T-Cell receptor natural killer cell therapy for sarcoma

IOME Bio claims breakthrough in cancer research

Sanofi drug reduces disease activity in relapsing MS

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!